The House of Lords Science and Technology Committee will continue
taking evidence for its inquiry into Life Sciences and the
Industrial Strategy on Tuesday 21 November.
recently said that an
effective industrial strategy should “stimulate a culture of
enterprise throughout our society”. The Committee will hear
’s views on how life sciences
can contribute to this objective and make the industrial strategy
a success.
Then Genomics England and the Royal Society will give
their views on how the Life Sciences Industrial Strategy’s
recommendations on the exploitation of health data should be
implemented in order to maximise economic and health benefits to
the UK.
Finally, the Committee will question the Chief
Medical Officer for England and the Department of Health Chief
Scientific Adviser on whether the NHS is equipped to provide the
level of innovation needed to implement the Life Sciences
Industrial Strategy.
The first evidence session will begin at 10.10 am,
when the Committee will question:
The second evidence session will begin at 11:00
am:
-
Sir John
Chisholm, Executive Chair,
Genomics England
-
Professor Dame Ottoline
Leyser, Royal
Society
The third evidence session will begin at 12:00
pm:
-
, Chief
Medical Officer for England
-
, DH Chief
Scientific Adviser, interim Government Chief Scientific
Adviser
Questions the witnesses are likely to be
asked include:
-
Much of the data within the NHS are held in
different forms and in separate systems that cannot always talk
to each other. How can these technical challenges be
overcome?
-
How do we ensure that the UK workforce has the
necessary skills to make sure Sir John Bell's strategy is a
success?
-
Is a life sciences strategy of this kind and a
'sector deal' the best way of optimising the relationship
between Government and business?
-
Who should be responsible for implementing the Life
Sciences Industrial Strategy and to whom should they be
accountable?
The evidence session will begin at 10.10 am
on Tuesday 21 November in Committee Room 2 of the House of
Lords.
